Skip to main content
balanceback Request Info

The Technology

Designed by Clinicians. Built for Better Decisions.

balanceback™ combines patented dual infrared goggle technology, proprietary software, and objective eye-movement analysis to support vestibular and neurological assessment.

Engineered for clinical efficiency, the system delivers reliable measurements, streamlined workflows, and a simplified hardware design with fewer components and connections.

Patented FDA-Cleared Trusted Since 2004

How it works

Objective Measurements You Can Trust

Every component of balanceback™ is designed around one goal: transforming eye movements into objective clinical evidence. From vestibular disorders to mTBI, Parkinson's disease, vestibular migraine, and other neurological conditions, balanceback™ helps clinicians evaluate patients with measurable data rather than observation alone.

  • Patented Dual Infrared Eye Tracking

    Patented dual infrared technology captures precise horizontal, vertical, and torsional eye movements during vestibular and neurological assessment.

  • Patented Plug-and-Play Technology

    The next-generation balanceback™ platform eliminates the traditional control box, reducing components, simplifying setup, and helping clinicians focus on patient care rather than system configuration.

  • Automatic Beat Detection & SPV

    The software detects nystagmus beats and computes slow-phase velocity automatically — and you keep the clinical interpretation. Nothing is hidden behind a black box.

  • Clinician-Editable Nystagmus Editor

    Review and refine every detected beat in the nystagmus editor. The analysis assists; the clinician stays in control of what counts.

  • Raw Trace Behind Every Number

    Access the raw eye-movement waveform at every timepoint. Every reported value traces back to the data it came from — the foundation of a defensible report.

  • Complete Vestibular & Neurological Assessment Platform

    Supports evaluation of peripheral vestibular disorders and central nervous system conditions, including mTBI, Parkinson's disease, vestibular migraine, cerebellar disorders, and other CNS pathologies.

Security & integration

Ready for your IT and compliance teams

Security is engineered into the platform by design and mapped to the HIPAA Security Rule. We label what's architected in and what's on the roadmap — honestly.

  • Encryption at rest (AES-256-GCM)

    By design

    PHI is encrypted at rest with AES-256-GCM authenticated encryption — each record bound to its own identity, so ciphertext can't be read or swapped.

  • Tamper-evident audit log

    By design

    An append-only, HMAC-SHA256 hash-chained audit log records every access and change; a broken chain is detected, not ignored.

  • Role-based access control

    By design

    Per-clinic, role-based permissions enforced by one central policy decision point govern who can test, sign, and administer.

  • HL7 ORU & FHIR R4 reporting

    On the roadmap

    Structured PDF reporting first; HL7 ORU and FHIR R4 DiagnosticReport export are on the integration roadmap.

  • SSO / OIDC

    On the roadmap

    Single sign-on via OIDC — and SAML for Azure AD — is on the roadmap for multi-site deployments.

Explore security & compliance

FDA-Cleared Class II Nystagmograph · 510(k) K042529 & K070729 · Records, displays & analyzes eye movements — not a diagnosis

See the technology in action

Request a guided walkthrough of the dual-infrared tracking, the nystagmus editor, and the raw-trace report.

Request a Demo Speak With a Specialist →